Literature DB >> 23901393

Pegloticase for treatment of tophaceous polyarticular gout.

Rebecca M Seifried1, Jefferson Roberts.   

Abstract

This is a case report of a patient with treatment resistant gout who was prescribed pegloticase and developed a severe reaction. A 30-year-old Hawaiian-Filipino man presented with a nine-year history of gout that progressed from episodic monoarticular arthritis, treated with aspiration and corticosteroid injections, to more aggressive disease with more frequent attacks requiring escalation of therapy. He was treated with systemic corticosteroids, colchicine and nonsteroidal anti-inflammatory drugs, but then required allopurinol. Despite aggressive therapy, the patient continued to have hyperuricemia and tophi developed even after treatment with febuxostat and probenicid. The patient became wheel chair bound due to his pain and, at that point, the decision was made to initiate treatment with pegloticase. The patient initially experienced significant improvement with treatment; however, he soon began to have elevation in his serum uric acid levels and developed a severe reaction during treatment.

Entities:  

Keywords:  infusion reaction; pegloticase; tophi; treatment resistant gout

Mesh:

Substances:

Year:  2013        PMID: 23901393      PMCID: PMC3727571     

Source DB:  PubMed          Journal:  Hawaii J Med Public Health        ISSN: 2165-8242


  8 in total

Review 1.  Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?

Authors:  Fernando Perez-Ruiz; Frédéric Lioté
Journal:  Arthritis Rheum       Date:  2007-10-15

Review 2.  Epidemiology of gout.

Authors:  Arthur L Weaver
Journal:  Cleve Clin J Med       Date:  2008-07       Impact factor: 2.321

3.  Gout medication treatment patterns and adherence to standards of care from a managed care perspective.

Authors:  Chaitanya A Sarawate; Kathleen K Brewer; Wenya Yang; Pankaj A Patel; H Ralph Schumacher; Kenneth G Saag; Alan W Bakst
Journal:  Mayo Clin Proc       Date:  2006-07       Impact factor: 7.616

4.  2011 Recommendations for the diagnosis and management of gout and hyperuricemia.

Authors:  Max Hamburger; Herbert S B Baraf; Thomas C Adamson; Jan Basile; Lewis Bass; Brent Cole; Paul P Doghramji; Germano A Guadagnoli; Frances Hamburger; Regine Harford; Joseph A Lieberman; David R Mandel; Didier A Mandelbrot; Bonny P McClain; Eric Mizuno; Allan H Morton; David B Mount; Richard S Pope; Kenneth G Rosenthal; Katy Setoodeh; John L Skosey; N Lawrence Edwards
Journal:  Postgrad Med       Date:  2011-11       Impact factor: 3.840

Review 5.  Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.

Authors:  Kuang-Hui Yu
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2007-02

Review 6.  New insights into the epidemiology of gout.

Authors:  Michael Doherty
Journal:  Rheumatology (Oxford)       Date:  2009-05       Impact factor: 7.580

7.  Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population.

Authors:  Katrine L Wallace; Aylin A Riedel; Nancy Joseph-Ridge; Robert Wortmann
Journal:  J Rheumatol       Date:  2004-08       Impact factor: 4.666

8.  Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.

Authors:  Michael A Becker; H Ralph Schumacher; Patricia A MacDonald; Eric Lloyd; Christopher Lademacher
Journal:  J Rheumatol       Date:  2009-03-13       Impact factor: 4.666

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.